Aquestive Therapeutics, Inc. financial data

Symbol
AQST on Nasdaq
Location
30 Technology Drive, Warren, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 471 % +16.4%
Quick Ratio 37.6 % -2.08%
Debt-to-equity -270 % -17.8%
Return On Equity 109 % +197%
Return On Assets -63.9 % -126%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.7M shares +9.51%
Common Stock, Shares, Outstanding 99.4M shares +9.11%
Entity Public Float 207M USD +151%
Common Stock, Value, Issued 99K USD +8.79%
Weighted Average Number of Shares Outstanding, Basic 99.3M shares +9.26%
Weighted Average Number of Shares Outstanding, Diluted 99.3M shares +9.26%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 44.1M USD -24.4%
Research and Development Expense 19.7M USD +21.5%
Costs and Expenses 96.7M USD +31.5%
Operating Income (Loss) -52.6M USD -246%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -65.1M USD -153%
Income Tax Expense (Benefit) -14K USD +64.1%
Net Income (Loss) Attributable to Parent -65M USD -153%
Earnings Per Share, Basic 0 USD/shares -81.6%
Earnings Per Share, Diluted 0 USD/shares -103%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.5M USD -32.6%
Inventory, Net 8.13M USD +16.6%
Assets, Current 81.7M USD -21.4%
Property, Plant and Equipment, Net 3.86M USD -1.61%
Operating Lease, Right-of-Use Asset 4.91M USD -9.64%
Other Assets, Noncurrent 3.21M USD -24.3%
Assets 93.7M USD -20.3%
Accounts Payable, Current 12M USD +110%
Employee-related Liabilities, Current 3.53M USD +32.3%
Accrued Liabilities, Current 5M USD -11.9%
Contract with Customer, Liability, Current 1.09M USD +4.4%
Liabilities, Current 23.2M USD +66.6%
Long-term Debt and Lease Obligation 32.5M USD +18.1%
Contract with Customer, Liability, Noncurrent 19.9M USD -8.37%
Operating Lease, Liability, Noncurrent 4.67M USD -10.9%
Other Liabilities, Noncurrent 2.05M USD +1.23%
Liabilities 166M USD +8.63%
Retained Earnings (Accumulated Deficit) -400M USD -19.4%
Stockholders' Equity Attributable to Parent -72.6M USD -105%
Liabilities and Equity 93.7M USD -20.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.4M USD -125%
Net Cash Provided by (Used in) Financing Activities 20.6M USD -74.7%
Net Cash Provided by (Used in) Investing Activities -135K USD -366%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 99.4M shares +9.11%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.89M USD -104%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.5M USD -32.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1M USD -31.6%
Deferred Tax Assets, Valuation Allowance 94.6M USD +12.5%
Deferred Tax Assets, Gross 95.3M USD +12.6%
Operating Lease, Liability 5.24M USD -7.99%
Depreciation 586K USD -38.3%
Payments to Acquire Property, Plant, and Equipment 135K USD +366%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -65M USD -153%
Lessee, Operating Lease, Liability, to be Paid 8.41M USD -13.1%
Property, Plant and Equipment, Gross 47.6M USD +1.06%
Operating Lease, Liability, Current 570K USD +25.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.35M USD +2.12%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.32M USD +2.65%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.17M USD -20.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.18M USD -12.3%
Deferred Tax Assets, Operating Loss Carryforwards 34.7M USD +27.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.18M USD -11.1%
Additional Paid in Capital 327M USD +9.34%
Amortization of Intangible Assets 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 7.45M USD +54.7%
Interest Expense 9.09M USD +48.9%